ANDA 208719, held by Zydus Pharms. Doxazosin Mesylate.
As of Nov 16, 2026, ANDA 208719 (Doxazosin Mesylate), held by Zydus Pharms, was first approved by FDA on Jul 7, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 7, 2017 | Original application | Approved |
| Doxazosin MesylateEQ 1MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 2MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 4MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 8MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters